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Abstract 
 
Background 
This study examined the impact of recurrent episodes of acute kidney injury (AKI) on patient 
outcomes.  
 
Methods 
The Welsh National electronic AKI reporting system was used to identify all cases of AKI in 
patients ≥18yrs of age between April 2015 and September 2018. Patients were grouped 
according to the number of AKI episodes they experienced with each patient’s first episode 
described as their index episode. We compared the demography and patient outcomes of 
those patients with a single AKI episode with those patients with multiple AKI episodes.  
Analysis included 153,776 AKI episodes in 111,528 patients.  
 
Results  
Of those who experienced AKI and survived their index episode 29.3% experienced a second 
episode, 9.9% a third episode, and 4.0% experienced four or more episodes. Thirty-day 
mortality for those patients with multiple episodes of AKI was significantly higher than for 
those patients with a single episode (31.3% vs. 24.9%, p<0.001). Following a single episode, 
recovery to baseline renal function at 30 days was achieved in 83.6% of patients and was 
significantly higher than for patients who had repeated episodes (77.8%, p<0.001).  For 
surviving patients non-recovery of renal function following any AKI episode was 
significantly associated with a higher probability of a further AKI episode (33.4% vs. 41.0%, 
p<0.001). Furthermore, with each episode of AKI the likelihood of a subsequent episode also 
increased (31.0% vs. 43.2% vs. 51.2% vs. 51.7% following a first, second, third and fourth 
episode, p<0.001 for all comparisons).  
 
Conclusions 
The results of this study provide an important contribution to the debate regarding the need 
for risk stratification for recurrent AKI.  The data suggests that such a tool would be useful 
given the poor patient and renal outcomes associated with recurrent AKI episodes as 
highlighted by this study.  
 
Keywords: Acute Kidney Injury (AKI) 
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Introduction 
 
Acute Kidney Injury (AKI) is associated with increased patient morbidity and mortality 
1, 2
. 
Whilst in-hospital consequences of AKI are well described, consequences beyond the index 
event are less well characterized.  Based on a presumption that early identification may help 
raise standards of care and improve patient outcomes, an automated real time electronic (e)-
alert system for AKI based on the Kidney Disease: Improving Global Outcomes (KDIGO) 
change in creatinine diagnostic criteria has been implemented nationally across all areas of 
the National Health Service (NHS) in England and Wales. Using the electronic AKI alert, we 
have developed a centralized data collection system to provide a comprehensive 
characterization of the incidence and outcomes of AKI identified by an electronic alert in 
Wales 
3-5
.  
 
Previous data suggest that AKI is associated with higher rates of re-hospitalisation, with up to 
20% of patients readmitted within 30 days 
6
.  Relatively few studies however, have described 
the epidemiology of recurrent AKI.  In the largest study to date, Liu et al. in a study of 38659 
patients who experienced a hospitalised episode of AKI, identified a second AKI episode in 
28.6% of patients. This is similar to that reported by Siew et al. demonstrating a 25% 
recurrence rate for AKI within 12 months of discharge. The latter study however, described 
cases from a regional Veterans Administration database and therefore focused predominantly 
on a hospitalized male patient cohort.  Other studies addressing recurrent AKI are relatively 
small in patient numbers 
7, 8
, or focus on specific patient cohorts 
9, 10
.  The aims of this study 
were to determine the incidence and outcomes of repeated episodes of AKI and identify 
potential risk factors for recurrence from a large population based data set.   
 
Materials and Methods 
 
This case series study used the Welsh National electronic alerting system for AKI to identify 
all cases of AKI in patients over the age of 18 years between April 2015 and September 2018. 
The Medical Record Number, a unique reference number allocated to patients registered in 
the National Laboratory Information Management System, was used as the patient identifier.  
The study has been approved under the conditions of ‘Service Evaluation Project 
Registration’. 
 
The electronic alerting system generates alerts by comparing a current creatinine value to 
historic creatinine measurements for the same patient in real time.  It defines AKI according 
to KDIGO increase in creatinine parameters 
3
. An AKI episode was defined as a period of 30 
days. Any AKI e-alert for the same patient within 30 days of the initial alert was not 
considered a new episode. The first AKI episode was defined as the index episode. To 
examine the impact of recurrent episodes, patients were classified as either having one 
episode, two episodes, three episodes, or four or more episodes. 
 
To avoid spurious results resultant from fluctuations in creatinine related to renal replacement 
therapies, dialysis patients, patients with a known renal transplant, and alerts generated in 
renal ward settings were excluded from the analysis 
3
.   
In addition to measurements of renal function, data was collected on patient age, gender, 
stage of index AKI episode, pre-existing chronic kidney disease (CKD) (eGFR was 
calculated using the CKD Epidemiology Collaboration eGFR equation 
11
  and pre-existing 
CKD was defined as an eGFR<60ml/min per 1.73 m
2
 derived from the baseline serum 
creatinine (SCr) associated with the index episode), and the clinical location at which the 
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index episode was generated.  An episode was defined as hospital acquired (HA)-AKI if the 
initial alert was transmitted by a blood test request in an inpatient or ITU & High 
Dependency setting. All other episodes were defined as community acquired (CA)-AKI. 
 
Data on patient mortality was collected from the Welsh Demographic Service 
12
.   Recovery 
was defined as achievement of a SCr value during the episode no longer in keeping with the 
definition of AKI when compared to the baseline SCr value associated with the episode. 
Patients were only included in the recovery analysis if they survived their episode and had at 
least one SCr test during the episode. Socioeconomic classification of patients was derived 
from the Welsh Index of Multiple Deprivation score (WIMD) 
13
. This is Welsh 
Government’s official measure of relative deprivation in which the population of Wales is 
divided into 1909 geographical units called lower super output areas (LSOAs) each with an 
average population of 1600 people.  The WIMD score is constructed from a weighted sum of 
the deprivation score for each of the following domains: Income (23.5%),   Employment 
(23.5%), Health (14.0%), Education (14.0%), Access to Services (10.0%), Community Safety 
(5.0%), Physical Environment (5.0%), and Housing (5.0%).   Patients were grouped 
according to the WIMD score by their postcode and corresponding LSOA of residence, and 
the ranked data were categorised into percentiles, with percentile 1 being the most socio-
economically deprived and percentile 100 being the least deprived.  
 
Statistical analysis was carried out using SPSS software, version 25 (IBM SPSS, Chicago, I). 
Student’s t test was used for analysis of normally distributed data. Categorical data were 
compared using a Pearson chi-squared test. Kaplan Meier analysis was used to estimate and 
compare survival of patient groups. Binomial logistic regression was used to understand 
whether 30 day AKI associated mortality, and recovery from an AKI episode can be 
predicted by the number of episodes incurred by a patient. We did this analysis both 
unadjusted and adjusted for patient demographic covariates which included pre-existing CKD, 
AKI stage of index episode, AKI type of index episode, gender, and age.  P values less than 
0.05 were considered statistically significant. 95% confidence intervals for binomial data 
were defined as 1.96 multiplied by the standard error. 
 
Data was collected from all Health boards in the NHS in Wales, representing a population of 
3.06 million people. A total of 153,776 episodes of AKI in 111,528 patients were identified.  
Average follow up time for index episodes was 448.5 ±401.4 days with a median of 349.3 
days.  Details of cohort creation are shown in Figure 1.  
 
Results 
Patient Characteristics   
The distribution of AKI severity for the index episode was AKI1 78.4%, AKI2 14.2% and 
AKI3 7.4%.  The mean age of the whole cohort was 70.91 ±17.3 years.  Fifty-three percent of 
the AKI patients were female.  Pre-existing CKD was identified in 28.3%.  50.99% of cases 
were HA-AKI and 49.01% CA-AKI.  
 
Of those who experienced AKI and survived the index episode 29.3% (26513) experienced a 
second episode, 9.9% (8920) a third, and 4.0% (3618) experienced four or more episodes.  In 
total this represents 68761 recurrent AKI episodes.  The second episode occurred a mean of 
231 ±358 days following the first episode, the third episode a mean of 169 ±184 days 
following the second, the fourth a mean of 134.8 ±145 days following the third episode.  
Patient demographics and location of the index episode are shown in Table 1.  
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Patient demographics associated with recurrent AKI   
Patients experiencing recurrent AKI were significantly older than those who had a single 
episode (≥2 episodes 72.22 ±15.2 years vs. 1 episode 70.49 ±17.9, p<0.001).  For those 
patients with repeated episodes, those who experienced 2 episodes were significantly older 
(73.22 ±15.08 years) than those who experienced three episodes (71.84 ±14.85 years, 
p<0.001) who were in turn, significantly older than those who experienced four or more 
episodes (67.94 ±15.49 years, p<0.001).  In those surviving the first AKI episode, a higher 
proportion of male patients experienced recurrent episodes of AKI (≥2 episodes: Male 29.6% 
vs. Female 25.9% p<0.001).   
 
A higher percentage of patients with repeated episodes of AKI had pre-existing CKD 
compared to those who experienced only one episode (≥2 episodes 35.1% vs. 1 episode 
28.8%).  There was also a significantly higher percentage of pre-existing CKD in patients 
who experienced 2 (35.6%) or 3 (33.3%) recurrent episodes compared to those who 
experienced ≥4 episodes (31.1%, p<0.001).  
 
The severity of the index AKI episode was assessed by AKI stage at presentation. There was 
significantly more stage 1 index episodes for patients who had multiple episodes, compared 
to patients who had a single episode. (1 episode: Stage 1 78.2%, stage 2 14.6%, stage 3 7.3%, 
≥2 episodes: Stage 1 79.4%, stage 2 13.0%, stage 3 7.6%, p<0.001).   
 
For surviving patients with biochemistry data available on renal outcome, non-recovery of 
renal function following any AKI episode was associated with a higher probability of a 
further AKI episode (33.4% vs. 41.0%, p<0.001).  Furthermore, with each episode of AKI 
the likelihood of another subsequent episode also increased (Figure 2).  If renal function 
returned to baseline the likelihood of at least one further episode of AKI rose from 30.1% 
following the first episode to 48.3% following 4 AKI episodes.  If renal function did not 
recover to baseline, the likelihood of at least one further episode of AKI rose from 35.3% 
following the first episode to 59.7% following 4 AKI episodes.   
 
Recurrent episodes of AKI were more common following an index case of HA-AKI 
compared to an index case of CA-AKI.  Location of the index episode did not influence the 
likelihood of a recurrent episode. Figure 3 shows the full patient journey for patients who had 
multiple episodes, and highlights that recurrent episodes were more likely to be the same type 
as their index episodes. A second episode of AKI occurred in 28.9% of patients surviving an 
index HA-AKI episode compared to 26.4% patients surviving an index CA-AKI episode 
(p<0.001).  Similarly, compared to CA, more patients surviving an HA index episode had a 
third episode and four or more episodes (3 episodes: 7.9% vs. HA-AKI 8.8%, p<0.001, ≥4 
episodes: 5.2% vs. HA-AKI 6.3% p<0.001).  To assess the association between recurrent 
AKI and social deprivation we looked at the mean WIMD score where a lower WIMD score 
corresponds to a higher level of social deprivation. Recurrent AKI was associated with 
greater social deprivation as the mean WIMD score was significantly lower for patients with 
recurrent AKI episodes (WIMD score 46.9±28.0) compared to those with a single AKI 
episode (WIMD score 47.9±28.3 p<0.001). 
 
Significance of AKI 
Mortality:  Thirty-day mortality following a single episode of AKI was 24.9% (Figure 4A).  
Repeated episodes of AKI (i.e. 2 or more episodes) was associated with significantly higher 
thirty-day mortality (31.3%) than a single episode (p<0.001). 30-day mortality was also 
significantly higher for patients who experienced 2 (31.4%), or 3 (33.6%) episodes compared 
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to those who experienced ≥4 episodes (28.2%) of AKI (p<0.001). Kaplan-Meier curves 
(censored at three years of follow up) showing survival depending on the number of AKI 
episodes are in Figure 4B.  Censored survival was significantly better for patients who had a 
single episode of AKI compared to multiple episodes (p<0.001), but was not significantly 
different for patients who experienced 2, 3 or ≥4 episodes. Overall mortality with a maximum 
follow up time of 1330 days was 24.9% for patients with one episode, and 31.3% for patients 
with multiple episodes. This is in comparison with the age-standardised mortality rate for 
Wales of 1,035.6 per 100,000 population
12
.   
Table 2 shows that males were significantly more likely to experience death within 30 days 
compared to females. Moreover the likelihood of death increased significantly with age, if a 
patient had pre-existing CKD, and if the index episode was hospital-acquired, and stage 3. 
Binary logistic regression also showed that for patients who experienced two episodes, the 
odds of dying within 30 days were 38% (OR=1.38, p<0.001) higher than for patients who 
experienced just one episode, 50% (OR=1.50, p<0.001) for three episodes, and 18% 
(OR=1.18, p<0.001) for four or more. The adjusted values in table 2 show that when adjusted 
for all other variables, the odds of death increased for all groups except those patients with 
two episodes. 
 
Thirty-day renal outcome: For each AKI episode between 14-19% of patients had no 
biochemical data available to assess recovery of renal function and were excluded.  
Following a single episode, recovery was achieved in 83.6% of patients (Figure 5).  This was 
significantly higher than for patients who had repeated episodes (77.8%, p<0.001).  Recovery 
was also lower for patients experienced 3 (74.4%), or ≥4 episodes (73.9%) compared to 
patients who experienced only 2 episodes of AKI (79.2%, p<0.001).  
Table 3 shows that males were significantly less likely to recover compared to females. 
Moreover the likelihood of recovery increased significantly with age, and if the index episode 
was hospital-acquired, and decreased if a patient had pre-existing CKD, and the index 
episode was stage 3. Binary logistic regression also showed that for patients who experienced 
two episodes, the odds of recovering were 26% (OR=0.75, p<0.001) lower than for patients 
who experienced just one episode, 43% (OR=0.57, p<0.001) for three episodes, and 46% 
(OR=0.54, p<0.001) for four or more. The adjusted values in table 3 show that when adjusted 
for all other variables, the odds of recovery increased for all groups. 
 
Discussion 
 
Previous studies have suggested that AKI is a risk factor for CKD progression 
18-20
.  
Observational studies link the progression of CKD including the development of end stage 
renal failure to previous episodes of AKI.  Few studies have however examined the 
epidemiology or impact of recurrent episodes of AKI.  A study focused on patients with 
Diabetes Mellitus suggests that AKI episodes are associated with a cumulative risk for 
developing advanced CKD 
21
, and studies in critically ill patients suggest that recurrent AKI 
is associated with worse outcomes 
8, 10
.  A small single centre retrospective study of only 350 
patients surviving AKI suggested that development of CKD was more likely with recurrent 
AKI
8
. In what is to our knowledge the largest study to date, using a national data set we have 
shown that roughly a third of patients who have an episode of AKI will experience at least 
one further episode and a significant number of patients experience multiple episodes.  This 
data is similar to that of Liu et al. in which almost a third of 40,000 hospitalised AKI cases 
experienced an episode of recurrent AKI during a median follow up of 1.8 years 
15
.  Our data 
is also consistent with the data of Siew et al., drawn from almost 12,000 AKI cases based on 
a regional Veterans Administration database, in which almost one in eight patients 
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experienced two recurrences 
14
.  Our study however is drawn on over 150,000 episodes and it 
is of note that we have not focused on hospitalised patients and instead used population based 
data.  We have previously demonstrated that a focus on hospitalised patients with a diagnosis 
based on retrospective coding data leads to significant under-reporting of AKI compared to 
electronic AKI alerts 
3, 22, 23
.   
 
The significance of repeated episodes is highlighted by the increase in mortality for patients 
who experience multiple episodes.    This increase in short and longer term mortality was 
higher for all cohorts with repeated AKI episodes.  Regression analysis also showed that the 
likelihood of death within 30 days of an AKI episode was higher for patients with recurrent 
episodes compared to patients with a single episode. Whilst the highest short term mortality 
was seen in the groups with either two or three AKI episodes, 30-day mortality in those 
experiencing four or more episodes remains higher than those experiencing only one episode. 
Although the group of patients who experience four or more episodes contained over 3,500 
patients, this was the smallest cohort and therefore the lower mortality should be interpreted 
cautiously. Moreover, it is notable that 30-day mortality does not increase monotonically 
beyond the third episode of AKI.  Rather this could represent survivor selection bias, since to 
have a fourth episode of AKI, patients have already survived three episodes as is illustrated in 
the Kaplan-Meier curves. The lack of a step wise increase in mortality with each recurrent 
episode of AKI likely represents survival bias.  This is supported by the data that 
demonstrates that a higher proportion of the patients who experience recurrent episodes of 
AKI, have AKI stage 1 at the index episode whilst a higher mortality is related to AKI stages 
2 and 3. The longer term censored data in contrast suggest that mortality for all repeated 
episodes is similar and significantly higher than for a single episode.  Our data also suggest 
that each additional episode of renal injury makes recovery of renal function less likely.  
Regression analysis showed that the likelihood of recovery was lower for patients with 
recurrent episodes compared to patients with a single episode. It should be noted that baseline 
renal function is reset at each AKI episode not to compound recovery data from “hangovers” 
related to any preceding episodes. The data also suggest that each repeated episode carries a 
worse outcome, in terms of mortality and deterioration in renal function.  This is a significant 
observation, as non-recovery from AKI is an important factor determining long-term 
outcome and CKD progression 
7, 18, 24
.  
 
A first step in preventing recurrent AKI is to identify patients at highest risk of having 
multiple AKI episodes.  The concept of a “drug holiday” and the cessation of potentially 
nephrotoxic medication during an AKI episode, and also for those at risk of developing AKI 
due to an inter-current illness is widely advocated.  Generally, beyond either the acute AKI 
episode or the acute illness placing a patient at risk, current practice is to restart these 
medications.  If there is a cohort of patients in whom the likelihood of recurrence can be 
predicted, the benefit of re-starting such medication needs to be balanced by the risk of AKI 
recurrence.  Our data suggest those most likely to have repeated episodes are older patients, 
with pre-existing CKD and those with incomplete recovery of their renal function following 
an acute episode.  Interestingly the data also suggest that patients from socially deprived 
areas are at higher risk of recurrent episodes.  Previously we have demonstrated that social 
deprivation is associated with higher incidence and worse outcome following AKI 
25
.  This 
was related to a greater burden of CKD at an earlier age.   Interestingly the severity of AKI at 
presentation of the index case was not useful in predicting recurrent episodes, despite a 
significant proportion of patients having AKI stage 2 or 3.  This is consistent with the 
observations of Liu et al. in which severity of AKI was not associated with recurrent AKI 
15
. 
This may in part be driven by higher rates of death observed in this population 
3
.  
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Current evidence suggests post discharge care may improve outcomes for patients discharged 
from hospital following medical emergencies 
26, 27
. For example, following acute myocardial 
infarction, early follow up with a cardiologist is associated with decreased mortality and 
improved compliance with secondary preventative measures 
28, 29
.  The follow-up of patients 
following an AKI episode remains undefined.  Not all patients who experience an episode of 
AKI can or should be followed up in a specialist clinic, given the large number of patients 
this would entail and the fact that in the majority of cases AKI is not indicative of intrinsic 
renal disease.  Harel et al. 
30
, however suggest specialist follow-up following AKI does 
translate into better outcomes.  This study suggests that nephrologist follow-up improves all-
cause mortality of severe AKI survivors, although this study focused only on patients who 
required dialysis during an inpatient AKI episode. Published data suggest that less than 10% 
of patients who experience an episode of dialysis-requiring AKI see a nephrologist within the 
first year 
31
. Dialysis requiring AKI however represents only a small minority of patients who 
experience an episode of AKI.  An alternative approach to identify who might benefit from 
specialist follow up may be to highlight those most likely to experience recurrent AKI 
episodes. This would optimize a patient’s chance of avoiding repeated AKI episodes which 
are associated with poor outcomes.  We suggest that patients with pre-existing CKD who 
suffer AKI and those whose renal function fails to recover to its pre-AKI baseline would be 
two overlapping cohorts which may benefit from specialist nephrology referral and follow up.   
 
Although this study is to our knowledge the first national study using an e-alert based system 
to characterise the magnitude and impact of recurrent AKI, its findings need to be qualified 
by its limitations. Using an IT based approach precludes inclusion of clinical information, 
such as patient co-morbidity and linkage to primary care data sets, and lacks the cause of AKI, 
the need for RRT, and cause of death.  As a result, we were unable to examine the 
relationship between patient clinical characteristics and the rate of AKI recurrence.  Previous 
data suggest that patient related chronic conditions such as heart failure, liver disease and 
cancer all associate with a higher rate of recurrent AKI 
14, 15
.  Future studies able to access 
detailed clinical data would allow development of a formal risk prediction tool for recurrent 
AKI using a similar approach to what we have used for the RISK study to predict an index 
episode of AKI 
16
.  Similarly, the use of biochemistry data precludes the use of urine output 
based definitions of AKI, although it should be noted that this data is not systematically 
available and rarely accessible to large population based studies.  Finally, the diagnosis of 
AKI is made by comparing creatinine values on an individual patient against previous results.  
This approach does consequently exclude patients with no previous measurements of 
creatinine on the system.  An alternative suggestion has been the use of population based 
estimated reference creatinine measures 
17
. Currently however, in our clinical setting when a 
creatinine value is above the reference range and doesn’t generate an alert, a message to 
highlight the raised value accompanies the result report.   
 
The strengths of our study include the size of the patient data set and the length of follow up.  
To our knowledge this is the largest published report addressing recurrent AKI with over 
150,000 AKI episodes.  Due to its size the data set included a substantial representation of all 
stages of AKI including those with more severe AKI, as well as a broad demography.  The 
data therefore allows the results to be generalized to broader populations than previously 
published studies. Use of the electronic alerting system provides access to cases of AKI 
which occur in both hospital and community settings, including primary care, and therefore 
overcomes some limitations inherent in studies of AKI in hospitalized cohorts or in which 
AKI diagnosis is reliant on hospital coding 
32-35
.  
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In conclusion the results of this study provide an important contribution to the debate 
regarding the need for risk stratification for recurrent AKI.  The data suggest that such a tool 
would be useful given the poor patient and renal outcomes associated with recurrent episodes 
of AKI as highlighted by this study.  Further work is however required to determine the 
specific process of care and interventions to affect clinical outcomes in those patients at high 
risk of recurrent AKI.   
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Table 1: Demography of patients with one AKI episode, two AKI episodes, three AKI episodes and four or more AKI episodes 
  1 episode  2 episodes 3 episodes ≥4 episodes 
Number of patients, n (% of all patients)  85015 (76.2) 17593 (15.8) 5302 (4.8) 3618 (3.2) 
Mean Age ±SD at index episode, yr  70.49 ±17.9 73.22 ±15.1 71.84 ±14.84 67.94 ±15.49 
Gender, % (n) 
 
 
Male 
Female 
 
46.3 (39353) 
53.7 (45662) 
 
 
47 (8428) 
52.1 (9165) 
 
49.8 (2638) 
50.2 (2664) 
 
47.9 (1732) 
52.1 (1886) 
Pre-existing CKD, % (n)  28.8 (24493) 35.6 (6260) 33.3 (1932) 31.1 (1125) 
AKI stage of index episode, % (n) 
 
 
Stage 1 
Stage 2 
Stage 3 
 
78.2 (66446) 
14.5 (12378) 
7.3 (6191) 
 
 
79.2 (13936) 
13.3 (2335) 
7.5 (1322) 
 
79.7 (4224) 
12.4 (655) 
7.9 (423) 
 
79.9 (2891) 
12.5 (452) 
7.6 (275) 
Type of AKI at index episode, % (n)  
CA-AKI 
HA-AKI 
 
50.9 (43286) 
49.1 (41729) 
 
51.7 (9086) 
48.3 (8507) 
 
51.4 (2724) 
48.6 (2578) 
 
49.1 (1777) 
50.9 (1841) 
Specialty of AKI at index episode, % of HA (n)  
General Medicine 
General Surgery 
Trauma & Orthopaedic 
Cardiology 
ITU & High Dependency 
 
 
22.8 (9501) 
13.0 (5427) 
9.2 (3855) 
7.5 (3137) 
10.1 (4232) 
 
24.3 (2071) 
12.8 (1091) 
8.1 (782) 
9.2 (782) 
9.0 (766) 
 
23.0 (593) 
13.9 (357) 
6.5 (168) 
9.8 (252) 
10.4 (269) 
 
21.7 (399) 
17.1 (314) 
5.7 (104) 
8.9 (164) 
12.3 (227) 
Mean WIMD percentile ±SD  47.91 ±28.32 47.41 ±28.15 46.20 ±27.96 46.06 ±28.11 
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Table 2: Adjusted and unadjusted odds ratios for risk factors in predicting 30 day AKI associated mortality 
  Unadjusted Adjusted* 
  OR (95% CI) P value OR (95% CI) P value 
Total number of episodes  
1 
2 
3 
≥4 
 
Reference 
1.38 (1.33-1.43) 
1.50 (1.41-1.59) 
1.18 (1.10-1.28) 
 
 
.000 
.000 
.000 
 
 
1.33 (1.28-1.38) 
1.53 (1.44-1.63) 
1.37 (1.27-1.48) 
 
 
.000 
.000 
.000 
Gender 
 
 
Female 
Male 
 
Reference 
1.28 (1.25-1.32) 
 
 
.000 
  
Pre-existing CKD 
 
 
No 
Yes 
 
Reference 
1.10 (1.07-1.14) 
 
 
.000 
  
AKI stage of index episode 
 
 
Stage 1 
Stage 2 
Stage 3 
 
Reference 
1.77 (1.71-1.84) 
1.91 (1.82-2.01) 
 
 
.000 
.000 
  
AKI type of index episode 
 
 
CA 
HA 
 
Reference 
1.61 (1.55-1.66) 
 
 
.000 
  
 
Age at index episode (yrs) 
  
1.04 (1.04-1.04) 
 
.000 
  
*Adjusted for Sex, Pre-existing CKD, AKI stage of index episode, AKI type of index episode, and age at index episode. OR, Odds ratio; CI, 
Confidence interval; CKD, chronic kidney disease. 
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Table 3: Adjusted and unadjusted odds ratios for risk factors in predicting recovery from an AKI episode 
  Unadjusted Adjusted* 
  OR (95% CI) P value OR (95% CI) P value 
Total number of episodes  
1 
2 
3 
≥4 
 
Reference 
0.75 (0.71-0.79) 
0.57 (0.52-0.62) 
0.54 (0.49-0.59) 
 
 
.000 
.000 
.000 
 
Reference 
0.79 (0.74-0.83) 
0.61 (0.56-0.67) 
0.56 (0.50-0.61) 
 
 
.000 
.000 
.000 
Gender 
 
 
Female 
Male 
 
Reference 
0.75 (0.73-0.79) 
 
 
.000 
  
Pre-existing CKD 
 
 
No 
Yes 
 
Reference 
0.71 (0.68-0.75) 
 
 
.000 
  
AKI stage of index episode 
 
 
Stage 1 
Stage 2 
Stage 3 
 
Reference 
0.71 (0.67-0.76) 
0.41 (0.39-0.44) 
 
 
.000 
.000 
  
AKI type of index episode 
 
 
CA 
HA 
 
Reference 
2.11 (2.02-2.21) 
 
 
.000 
  
 
Age at index episode (yrs) 
  
1.00 (1.00-1.01) 
 
.000 
  
*Adjusted for Sex, Pre-existing CKD, AKI stage of index episode, AKI type of index episode, and age at index episode. OR, Odds ratio; CI, 
Confidence interval; CKD, chronic kidney disease. 
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Figure legends 
 
Figure 1: Flow diagram of cohort creation, with exclusion and inclusion criteria. 
 
Figure 2: The impact of renal recovery of AKI episodes on the probability of recurrent AKI 
episodes. 76,744 patients survived and had recovery data available for their index (1st) 
episode (63,349, recovery; 13,395, non-recovery), 19,063 of those that recovered had a 
second episode and 4,726 of those that non-recovered had a second episode. 18,282 patients 
survived and had recovery data available for their 2nd episode (14,078, recovery; 4,204, non-
recovery), 5,863 of those that recovered had a third episode and 2,041 of those that non-
recovered had a third episode. 6,245 patients survived and had recovery data available for 
their 3rd episode (4,425, recovery; 1,820, non-recovery), 2,158 of those that recovered had a 
fourth episode and 1,041 of those that non-recovered had a fourth episode. 2,635 patients 
survived and had recovery data available for their 4th episode (1,859, recovery; 776, non-
recovery), 898 of those that recovered had a further episode and 463 of those that non-
recovered had a further episode. Error bars represent 95% confidence intervals. Asterisks 
represent statistically significant differences. 
 
Figure 3: Flow diagram of patient journey for patients with multiple episodes. 26,514 patients 
had more than one episode and were included in the analysis (13,588, CA; 12,926, HA) 
 
Figure 4: The impact of recurrent episodes of AKI on thirty-day mortality and patient 
survival. [A] Thirty-day mortality rates for patients with one AKI episode, two AKI episodes, 
three AKI episodes and four or more AKI episodes. Mortality data was available for 111,528 
patients (85,015, 1 episode; 17,953, 2 episodes; 5,302, 3 episodes; 3,618, ≥4 episodes). [B] 
Kaplan Meier survival curves for patients with one AKI episode, two AKI episodes, three 
AKI episodes and four or more AKI episodes. Error bars represent 95% confidence intervals. 
 
Figure 5: Recovery of renal function for patients with one AKI episode, two AKI episodes, 
three AKI episodes and four or more AKI episodes. 82,059 patients survived and had 
recovery data available (63,849, 1 episode; 12,068, 2 episodes; 3,544, 3 episodes; 2,598, ≥4 
episodes). Error bars represent 95% confidence intervals. 
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